It is inevitable to anticipate the development of laboratory abilities and their involvement in clinical research in a fast-paced world. The RESTORE study is one such incident that has drawn the interest of various specialists. Red blood cells that have been generated in a lab have been transfused into a patient in this trial who needs that blood. This procedure was the first to deliver lab-grown cells to another individual through a blood transfusion, which is an advancement in laboratory innovations. To make lab-grown blood, adult stem cells from the donor are cultured for 18 to 21 days in a nutritive solution. Cell development and expansion are encouraged by this. To generate 1-2 teaspoons of blood requires approximately 24 L of nutrient media. The blood is tested for the presence of antibodies after 6 months after which the volunteer test recipients are given another but a standard transfusion of unmanipulated cells from the same donors or, if they were given the latter first, they then get the in vitro generated blood cells second. Delivering a manufacturing process that can produce enough lab grown RBC at scale and creating a process that complies with good manufacturing practice standards are some of the challenges for the lab grown RBC production. The compliance issues of these lab grown RBCs with largescale erythroid cultures for a transfusion product may affect yield, put pressure on culture times, and raise costs; as a result, they must be taken into account and prepared for from the beginning.